Mrugacz Małgorzata, Krajewska Marzena, Bryl Anna, Szuszkiewicz Maciej
Uniwersytet Medyczny w Białymstoku, Samodzielna Pracownia Rehabilitacji Narzadu Wzroku.
Pol Merkur Lekarski. 2013 Jun;34(204):351-4.
Diabetes mellitus concerns a growing number of people in the world. Its complications are an important social problem. Diabetic macular edema (DME) is one of the leading causes of visual loss in the course of the disease. Deterioration of vision is typically the patients with long-standing, poorly controlled diabetes, both type 1 and 2. DME can occur at any stage of the disease. Because structural changes in the macula are reversible in the initial period, it is important to start treatment early. In the treatment of diabetic uses three techniques retinal laser--direct photocoagulation, photocoagulation a "grid" and the panphotocoagulation. The aim of this study was to evaluate the effectiveness of laser therapy in the treatment of diabetic macular edema.
The study included 90 patients (180 eyes) with DME, 50 women and 40 men aged from 18 to 80 years with a visual acuity of 0.08 to 0.7 with the best corrected on the Snellen chart. 9 people were with type 1 diabetes, 81 with type 2. 86 patients applied insulin, 4 people took drugs. Eye with poor visual acuity was qualified for the treatment. In all patients enrolled in the study visual acuity, anterior segment of the eye in the slit lamp and fundus by indirect ophthalmoscopy with Volk 78D lens were evaluated. DME was diagnosed on the basis of the results of fluorescein angiography and optical coherence tomography. In the patients laser therapy was performed twice: on day 1 after qualification and four months later. Performed two types of laser: the focal photocoagulation and the type of "grid" depending on the severity of DME. Retinal photocoagulation was performed using a diode laser 810 nm Diode Laser Systems OcuLight SL and SLx Iris Medical Models. Patients were monitored at 4 and 8 months after the laser therapy. The results were statistically analyzed.
Duration of diabetes less than 10 years was in 67 patients, over 10 years in 23. In patients with diabetes under 10 years predominated limited type of macular edema (92.65%), in patients over 10--diffuse (72.73%). As a result of the treatment in 34 patients (37.8%) visual acuity was improved. 91.18% of them had limited macular edema. In 47 patients (52.2%) showed the stabilization of vision. These patients had also more limited type of edema (74.47%). In 9 patients (10%) visual impairment were observed and they were mostly patients with diffuse macular edema (66.67%). Average visual acuity in patients with limited macular edema before laser therapy was 0.37 +/- 0.18. In the four months after the laser treatment improved slightly (0.38 +/- .18). After 8 months of treatment the average visual acuity in this group remained at a level of 0.44 +/- 0.16. In patients with diffuse macular edema output type visual acuity was significantly lower and averaged only 0.16 +/- 0.1. In 4 months after the laser was found in this group decreased vision (Vo = 0.13 +/- 0.08). In 8 months after surgery visual acuity averaged 0.15 +/- 0.09. Average visual acuity before laser therapy in this group was 0.36 +/- 0.17, and 8 months after was at the level of 0.43 +/- 0.16. In patients with diabetes more than 10 years laser therapy has not brought the desired effect, and visual acuity were as follows: before treatment--0.18 +/- 0.16 and 8 months after--0.17 +/- 0.14 (p < 0.0001). Average macular thickness before laser therapy in patients with limited edema was 348.14 +/- 33.47 microns. In 4 months after the laser has been observed decreased to 340.29 +/- 31.2 microns, and after 8 months of further withdrawal of edema to an average of 337.88 +/- 32.95 microns. In patients with diffuse type average macular thickness was 394.38 +/- 38.18. After 4 months of laser treatment exacerbation of edema (mean 399 +/- 38.08). After 8 months, the thickness of macula in this group was average 388.95 +/- 32.85.
Laser therapy is an effective type of treatment for DME. Better results after laser therapy are obtained in patients with a short-term macular edema and good visual acuity. In order to maintain useful visual acuity, patients with DME should undergo laser treatment in the early stages of the disease.
糖尿病在全球影响着越来越多的人。其并发症是一个重要的社会问题。糖尿病性黄斑水肿(DME)是该疾病导致视力丧失的主要原因之一。视力下降通常发生在1型和2型糖尿病病程长且控制不佳的患者中。DME可发生在疾病的任何阶段。由于黄斑的结构变化在初期是可逆的,因此早期开始治疗很重要。糖尿病视网膜病变的治疗采用三种激光技术——直接光凝、“格栅”光凝和全视网膜光凝。本研究的目的是评估激光治疗糖尿病性黄斑水肿的有效性。
本研究纳入90例(180只眼)DME患者,年龄18至80岁,其中女性50例,男性40例,Snellen视力表最佳矫正视力为0.08至0.7。1型糖尿病患者9例,2型糖尿病患者81例。86例患者使用胰岛素,4例患者服用药物。视力较差的眼纳入治疗。对所有纳入研究的患者评估视力、裂隙灯下眼前节以及使用Volk 78D透镜间接检眼镜检查眼底。根据荧光素血管造影和光学相干断层扫描结果诊断DME。对患者进行两次激光治疗:入选后第1天和4个月后。根据DME的严重程度进行两种类型的激光治疗:局灶性光凝和“格栅”型光凝。使用810 nm二极管激光系统OcuLight SL和SLx Iris Medical Models二极管激光进行视网膜光凝。在激光治疗后4个月和8个月对患者进行监测。对结果进行统计学分析。
糖尿病病程小于10年的患者67例,大于10年的患者23例。糖尿病病程小于10年的患者中,局限性黄斑水肿占主导(92.65%),病程大于10年的患者中,弥漫性黄斑水肿占主导(72.73%)。治疗后,34例患者(37.8%)视力提高。其中91.18%为局限性黄斑水肿。47例患者(52.2%)视力稳定。这些患者的水肿类型也多为局限性(74.47%)。9例患者(10%)出现视力损害,且大多为弥漫性黄斑水肿患者(66.67%)。局限性黄斑水肿患者激光治疗前平均视力为0.37±0.18。激光治疗4个月后略有提高(0.38±0.18)。治疗8个月后,该组平均视力维持在0.44±0.16水平。弥漫性黄斑水肿患者治疗前平均视力显著较低,仅为0.16±0.1。激光治疗4个月后,该组视力下降(Vo = 0.13±0.08)。手术后8个月,平均视力为0.15±0.09。该组激光治疗前平均视力为0.36±0.17,8个月后为0.43±0.16。糖尿病病程大于10年的患者激光治疗未取得理想效果,视力情况如下:治疗前——0.18±0.16,8个月后——0.17±0.14(p < 0.0001)。局限性水肿患者激光治疗前平均黄斑厚度为348.14±33.47微米。激光治疗4个月后降至340.29±31.2微米,8个月后水肿进一步消退,平均为337.88±32.95微米。弥漫性黄斑水肿患者平均黄斑厚度为394.38±38.18。激光治疗4个月后水肿加重(平均399±38.08)。8个月后,该组黄斑厚度平均为388.95±32.85。
激光治疗是DME的一种有效治疗方式。短期黄斑水肿且视力较好的患者激光治疗后效果更佳。为维持有用视力,DME患者应在疾病早期接受激光治疗。